UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 1719, 2009

Altus Pharmaceuticals Inc.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	0-51711	04-3573277
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

610 Lincoln Street, Waltham, Massachusetts		02451
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		781-373-6000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 83.01 ~~Other~~Notice ~~Events~~of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 1719, 2009, Altus Pharmaceuticals Inc. (~~"Altus"~~the or "weCompany") ~~entered~~submitted ~~into~~to anthe ~~option~~Listing ~~agreement~~Qualifications ~~(the~~Department ~~"Option~~of ~~Agreement")~~the ~~with~~Nasdaq ~~Vertex~~Stock ~~Pharmaceuticals~~Market ~~Incorporated~~ ("~~Vertex~~NASDAQ"), ~~granting~~an ~~Altus~~application orto ~~any~~transfer ~~of its successors~~ the ~~right~~listing ~~to purchase all~~ of ~~the~~its ~~right,~~common ~~title~~stock ~~and~~from ~~interest~~The ofNASDAQ ~~Vertex~~Global inMarket ~~and~~ to ~~Vertex's~~The ~~holdings~~NASDAQ ofCapital ~~Altus' redeemable preferred stock at a price of $1~~Market.5 On ~~million~~August ~~before December 20~~21, 2009~~. As a condition to exercising its option~~, ~~Altus~~the ~~must~~Company ~~enter~~received ~~into~~notice anfrom ~~agreement~~NASDAQ ~~with a third party under which~~ that ~~third~~its ~~party~~application ~~covenants~~ to ~~indemnify~~transfer ~~Vertex~~listing ~~for~~of ~~any~~its ~~portion~~common ofstock ~~the~~had ~~purchase~~been ~~price~~approved. ~~that~~The ~~Vertex~~transfer ~~might~~will be ~~required~~effective toat ~~divest in~~ the ~~case~~opening of athe ~~bankruptcy~~market ~~filing~~on byAugust ~~Altus. In connection with our 1999 reorganization~~26, ~~450,000~~2009. The ~~shares~~Company ofwill ~~redeemable~~continue ~~preferred stock were issued~~ to ~~Vertex~~trade ~~with~~under athe ~~value~~symbol ~~of $3~~"ALTU.1" ~~million.~~The ~~Vertex~~NASDAQ ~~has~~Capital noMarket ~~stockholder~~is ~~voting~~a ~~rights~~continuous ~~and~~trading ismarket ~~entitled~~that tooperates ~~receive~~in ~~dividends~~the atsame anmanner ~~annual~~as ~~rate~~The ofNASDAQ ~~$0.50~~Global ~~per share~~Market. All ~~Dividends~~companies ~~are~~listed ~~cumulative~~on ~~whether~~The orNASDAQ ~~not~~Capital ~~declared~~Market bymust ~~the~~meet ~~Board~~certain offinancial ~~Directors~~requirements and ~~have~~adhere ~~been~~to ~~accrued~~NASDAQ’s incorporate ~~the~~governance ~~amount of approximately $2~~standards.3 The ~~million~~Company atbelieves ~~June~~it ~~30,~~is ~~2009.~~in ~~Unless~~compliance ~~Altus~~with ~~exercises~~ the ~~above~~minimum ~~mentioned~~stockholders’ ~~option,~~equity ~~the~~requirement ~~redeemable~~and ~~preferred~~all ~~stock~~other isapplicable ~~redeemable~~criteria for ~~cash~~continued listing on orThe ~~after~~NASDAQ ~~December~~Capital 31Market, ~~2010~~but atfor the ~~option~~$1.00 ofbid ~~Vertex,~~price orrequirement. As ata ~~our~~result ~~option~~of atthe ~~any~~market ~~time~~transfer, atthe aCompany ~~price~~is ofno ~~$10.00~~longer ~~per~~subject ~~share~~to ~~plus~~delisting ~~accrued~~from ~~and~~NASDAQ ~~unpaid~~as ~~dividends.~~a ~~Upon~~result ~~liquidation,~~of ~~Vertex~~the ispreviously ~~entitled~~disclosed tostockholders’ ~~receive,~~equity ~~prior~~deficiency toas ~~any~~of ~~payment~~June ~~with~~30, ~~respect to the common stock~~2009, ~~$10.00~~but ~~per~~it ~~share~~will ~~plus~~need ~~accrued~~to ~~but~~comply ~~unpaid~~with ~~dividends. In~~The ~~addition,~~NASDAQ onCapital ~~August~~Market’s ~~14,~~continued ~~2009,~~listing ~~Jill~~requirements ~~Porter~~on ~~informed~~an ~~the~~ongoing ~~Altus~~basis. The ~~that~~Company ~~she~~expects isto ~~resigning~~have asat ~~Vice~~least ~~President,~~180 ~~Process~~days ~~Development~~to &meet ~~Engineering~~the ~~of Altus Pharmaceuticals Inc~~$1.,00 ~~effective~~bid ~~August~~price ~~21, 2009~~requirement.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Altus Pharmaceuticals Inc.
August 17, 2009	By:	Georges Gemayel
August 21, 2009	By:	Thomas J. Phair, Jr.
		Name: Georges Gemayel
		Name: Thomas J. Phair, Jr.
		Title: President and Chief Executive Officer
		Title: Vice President, Finance and Treasurer

Filing Compare · Altus Pharmaceuticals Inc.